The Federal Drug Administration (FDA) approved use of a new, innovative treatment for those in the early stages of ...
Medicare (and Medicare Advantage) provide some coverage for dementia, beginning with the diagnosis, says Baumgart.
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The good news is that anti-aging medications have moved from the realms of science fiction and are inching closer to reality.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...